Abbvie (ABBV) PT Cut to $60 at BMO Capital as Cautious Thesis Materializing Faster
Tweet Send to a Friend
BMO Capital analyst Alex Arfaei lowered his price target on Market Perform-rated Abbvie (NYSE: ABBV) to $60.00 (from $62.00), saying ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
